<inglise> Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts "similar medicinal product" and "clinical superiority" </inglise>
<eesti> KOMISJONI M&Auml;&Auml;RUS (E&Uuml;) nr 847/2000, millega kehtestatakse ravimi harva kasutatavaks ravimiks nimetamise kriteeriumi rakenduss&auml;tted ja m&otilde;istete "sarnane ravim" ning "kliiniline paremus" m&auml;&auml;ratlused 27. aprill 2000 </eesti>
<inglise> THE COMMISSION OF THE EUROPEAN COMMUNITIES, </inglise>
<eesti> EUROOPA &Uuml;HENDUSTE KOMISJON, </eesti>
<inglise> Having regard to the Treaty establishing the European Community, </inglise>
<eesti> v&otilde;ttes arvesse Euroopa &Uuml;henduse asutamislepingut, </eesti>
<inglise> Having regard to Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products(1), and in particular Articles 3 and 8 thereof, </inglise>
<eesti> v&otilde;ttes arvesse Euroopa Parlamendi ja n&otilde;ukogu 16. detsembri 1999. aasta m&auml;&auml;rust (E&Uuml;) nr 141/2000 harva kasutatavate ravimite kohta, (1) eriti selle artikleid 3 ja 8, </eesti>
<inglise> Whereas: </inglise>
<eesti> ning arvestades, et: </eesti>
<inglise> (1) Regulation (EC) No 141/2000 calls on the Commission to adopt provisions necessary for the implementation of Article 3 and to adopt definitions of "similar medicinal product" and "clinical superiority". </inglise>
<eesti> 1) m&auml;&auml;rus (E&Uuml;) nr141/2000 kutsub komisjoni v&otilde;tma vastu artikli 3 rakendamiseks vajalikke s&auml;tteid ja m&otilde;istete "sarnane ravim" ning "kliiniline paremus" m&auml;&auml;ratlusi; </eesti>
<inglise> (2) In order to implement Article 3 of Regulation (EC) No 141/2000, additional details on the factors that should be considered when establishing prevalence, likely return on investment and the satisfactory nature of alternative methods of diagnosis, prevention and treatment may be helpful for sponsors and the Committee for Orphan Medicinal Products. </inglise>
<eesti> 2) m&auml;&auml;ruse (E&Uuml;) nr 141/2000 artikli 3 rakendamisel v&otilde;ib sponsoritel ja harva kasutatavate ravimite komiteel olla kasulik arvesse v&otilde;tta t&auml;iendavaid &uuml;ksikasju leviku, investeeringu arvatava kasumi ning alternatiivsete diagnoosi-, v&auml;ltimis- ja ravimeetodite vastuv&otilde;etavuse kohta; </eesti>
<inglise> (3) This information should be presented in accordance with the guidance drawn up by the Commission pursuant to Article 5(3) of Regulation (EC) No 141/2000. </inglise>
<eesti> 3) see teave tuleks esitada koosk&otilde;las suunistega, mis komisjon koostab vastavalt m&auml;&auml;ruse (E&Uuml;) nr 141/2000 artikli 5 l&otilde;ikele 3; </eesti>
<inglise> (4) Given the nature of the medicinal products concerned, and the probability that the conditions to be treated are rare, it is not appropriate to lay down overly prescriptive requirements to establish that the criteria are met. </inglise>
<eesti> 4) arvestades k&otilde;nealuste ravimite olemust ja eeldust, et ravitavad seisundid on haruldased, ei ole kohane teha liiga &uuml;ksikasjalikke ettekirjutusi, kuidas t&otilde;estada vastavust kriteeriumidele; </eesti>
<inglise> (5) The assessment of the criteria referred to in Article 3 should be on the basis of information that is as objective as possible. </inglise>
<eesti> 5) artiklis 3 nimetatud kriteeriume tuleks hinnata v&otilde;imalikult objektiivse teabe alusel; </eesti>
<inglise> (6) Other Community measures in the field of rare diseases should be taken into account. </inglise>
<eesti> 6) arvestada tuleks teisi &uuml;henduse meetmeid haruldaste haiguste valdkonnas; </eesti>
<inglise> (7) In order to ensure appropriate respect of the market exclusivity provisions laid down in Article 8 of Regulation (EC) No 141/2000, it is necessary to lay down definitions of the concepts of "similar medicinal product" and "clinical superiority"; these definitions should take into account the work and experience of the Committee for Proprietary Medicinal Products in evaluating existing medicinal products, and the relevant opinions of the Scientific Committee on Medicinal Products and Medical Devices. </inglise>
<eesti> 7) m&auml;&auml;ruse (E&Uuml;) nr 141/2000 artikis 8 etten&auml;htud ainu&otilde;igust turul tagavate s&auml;tete j&auml;rgimiseks on vaja m&auml;&auml;ratleda "sarnase ravimi" ja "kliinilise paremuse" m&otilde;isted; need m&auml;&auml;ratlused peaksid arvestama ravimpreparaatide komitee t&ouml;&ouml;d olemasolevate ravimite hindamisel ning ravimite ja meditsiiniseadmete teaduskomitee asjakohaseid arvamusi; </eesti>
<inglise> (8) The definitions should be further supported by the guidelines foreseen by Article 8(5) of Regulation (EC) No 141/2000. </inglise>
<eesti> 8) m&auml;&auml;ratlusi peaksid t&auml;iendavalt toetama m&auml;&auml;ruse (E&Uuml;) nr 141/2000 artikli 8 l&otilde;ikes 5 etten&auml;htud suunised; </eesti>
<inglise> (9) These provisions should be updated regularly in the light of scientific and technical knowledge and experience with the designation and regulation of orphan medicinal products. </inglise>
<eesti> 9) neid s&auml;tteid tuleks korrap&auml;raselt ajakohastada, pidades silmas teaduse ja tehnika edusamme ning harva kasutatavate ravimite nimetamisel ja reguleerimisel saadud kogemusi; </eesti>
<inglise> (10) The measures provided for in this Regulation are in conformity with the opinion of the Standing Committee on Medicinal Products for Human Use, </inglise>
<eesti> 10) k&auml;esolevas m&auml;&auml;ruses etten&auml;htud meetmed on koosk&otilde;las inimtervishoius kasutatavate ravimite alalise komitee arvamusega, </eesti>
<inglise> HAS ADOPTED THIS REGULATION: </inglise>
<eesti> ON VASTU V&Otilde;TNUD K&Auml;ESOLEVA M&Auml;&Auml;RUSE. </eesti>
<inglise> Article 1 </inglise>
<eesti> Artikkel 1 </eesti>
<inglise> Purpose </inglise>
<eesti> Eesm&auml;rk </eesti>
<inglise> This Regulation lays down factors to be considered when implementing Article 3 of Regulation (EC) No 141/2000 on orphan medicinal products and establishes definitions of "similar medicinal product" and "clinical superiority" for the purposes of implementing Article 8 of the abovementioned Regulation. </inglise>
<eesti> K&auml;esolev m&auml;&auml;rus s&auml;testab tegurid, mida tuleb arvestada m&auml;&auml;ruse (E&Uuml;) nr 141/2000 harva kasutatavate ravimite kohta artikli 3 rakendamisel, ja kehtestab nimetatud m&auml;&auml;ruse artikli 8 rakendamise eesm&auml;rgil m&auml;&auml;ratlused "sarnane ravim" ja "kliiniline paremus". </eesti>
<inglise> It is intended to assist potential sponsors, the Committee for Orphan Medicinal Products, and competent authorities in the interpretation of Regulation (EC) No 141/2000. </inglise>
<eesti> See on kavandatud abiks v&otilde;imalikele sponsoritele, harva kasutatavate ravimite komiteele ja p&auml;devatele asutustele m&auml;&auml;ruse (E&Uuml;) nr 141/2000 t&otilde;lgendamisel. </eesti>
<inglise> Article 2 </inglise>
<eesti> Artikkel 2 </eesti>
<inglise> Criteria for designation </inglise>
<eesti> Nimetamise kriteeriumid </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> Prevalence of a condition in the Community </inglise>
<eesti> Haigusseisundi esinemissagedus &uuml;henduses </eesti>
<inglise> For the purpose of establishing, pursuant to the first subparagraph of Article 3(1) (a) of Regulation (EC) No 141/2000, that a medicinal product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10000 persons in the Community, the following specific rules shall apply and the documentation listed below shall be provided in accordance with the guidance drawn up pursuant to Article 5(3) of Regulation (EC) No 141/2000: </inglise>
<eesti> Selleks et vastavalt m&auml;&auml;ruse (E&Uuml;) nr 141/2000 artikli 3 l&otilde;ike 1 punkti a esimesele l&otilde;igule t&otilde;endada, et ravim on m&otilde;eldud eluohtliku v&otilde;i j&auml;&auml;valt invaliidistava haigusseisundi diagnoosimiseks, v&auml;ltimiseks v&otilde;i raviks ega m&otilde;juta &uuml;henduses rohkem kui viit inimest k&uuml;mnest tuhandest, tuleb kohaldada j&auml;rgmisi konkreetseid eeskirju ja esitada edaspidi loetletavad dokumendid, mis on koosk&otilde;las m&auml;&auml;ruse (E&Uuml;) nr 141/2000 artikli 5 l&otilde;ike 3 kohaselt koostatud suunistega: </eesti>
<inglise> (a) the documentation shall include appended authoritative references which demonstrate that the disease or conditions for which the medicinal product would be administered, affects not more than five in 10000 persons in the Community at the time at which the application for designation is submitted, where these are available; </inglise>
<eesti> a) dokumentatsioonile tuleb lisada usaldusv&auml;&auml;rsed viited, kui need on k&auml;ttesaadavad, mis n&auml;itavad, et haigus v&otilde;i haigusseisund, mille korral ravimit kasutataks, ei m&otilde;juta nimetamistaotluse esitamise ajal &uuml;henduses rohkem kui viit inimest k&uuml;mnest tuhandest; </eesti>
<inglise> (b) the data shall include appropriate details on the condition intended to be treated and a justification of the life-threatening or chronically debilitating nature of the condition supported by scientific or medical references; </inglise>
<eesti> b) andmed peavad sisaldama vajalikke &uuml;ksikasju ravida kavatsetava haigusseisundi kohta ja teaduslike v&otilde;i meditsiiniliste viidetega toetatud p&otilde;hjendust haigusseisundi eluohtliku v&otilde;i j&auml;&auml;valt invaliidistava olemuse kohta; </eesti>
<inglise> (c) the documentation submitted by the sponsor shall include or refer to a review of the relevant scientific literature, and shall provide information from relevant databases in the Community, where these are available. </inglise>
<eesti> c) sponsori esitatud dokumnetatsioonis peab olema &uuml;levaade asjakohasest teaduskirjandusest v&otilde;i viide sellele ning teave asjakohastest andmebaasidest &uuml;henduses, kui sellised on olemas. </eesti>
<inglise> Where no database in the Community is available, reference may be made to databases available in third countries, provided the appropriate extrapolations are made; </inglise>
<eesti> Kui &uuml;henduses pole &uuml;htki andmebaasi, v&otilde;ib viidata kolmandates riikides olemasolevatele andmebaasidele, kui on tehtud vajalikud ekstrapolatsioonid; </eesti>
<inglise> (d) where a disease or condition has been considered within the framework of other Community activities on rare diseases, this information shall be provided. </inglise>
<eesti> d) kui haigust v&otilde;i haigusseisundit on k&auml;sitletud seoses muude haruldaste haiguste ravimise meetmetega &uuml;henduses, esitatakse see teave. </eesti>
<inglise> In the case of diseases or conditions included in projects financially supported by the Community in order to improve information on rare diseases, a relevant extract from this information, including in particular, details of the prevalence of the disease or condition in question, shall be provided. </inglise>
<eesti> Kui haiguste v&otilde;i haigusseisundite korral saadakse &uuml;henduse rahalist tuge projektidest, mille &uuml;lesanne on saada lisateavet haruldaste haiguste kohta, tuleb esitada asjakohane v&auml;ljav&otilde;te sellest teabest, eelk&otilde;ige &uuml;ksikasjad k&otilde;nealuse haiguse v&otilde;i haigusseisundi esinemissageduse kohta. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> Potential for return on investment </inglise>
<eesti> Investeeringutasuvuse potentsiaal </eesti>
<inglise> For the purpose of establishing, pursuant to the second subparagraph of Article 3(1) (a) of Regulation (EC) No 141/2000, that a medicinal product is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the Community, and that without incentives it is unlikely that the marketing of the medicinal product in the Community would generate sufficient return to justify the necesary investment, the following specific rules shall apply and the appropriate documentation shall be provided in accordance with the guidance drawn up pursuant to Article 5(3) of Regulation (EC) No 141/2000: </inglise>
<eesti> Selleks et vastavalt m&auml;&auml;ruse (E&Uuml;) nr 141/2000 artikli 3 l&otilde;ike 1 punkti a teisele l&otilde;igule t&otilde;endada, et ravim on m&otilde;eldud eluohtliku, t&otilde;siselt invaliidistava v&otilde;i t&otilde;sise ja kroonilise haigusseisundi diagnoosimiseks, v&auml;ltimiseks v&otilde;i raviks &uuml;henduses ning et ilma soodustusteta ei ole t&otilde;en&auml;oline, et ravimi m&uuml;&uuml;k &uuml;henduses annaks piisavat tulu vajaliku investeeringu &otilde;igustamiseks, kohaldatakse j&auml;rgmisi konkreetseid eeskirju ja esitatakse edaspidi loetletud dokumendid, mis on koosk&otilde;las m&auml;&auml;ruse (E&Uuml;) nr 141/2000 artikli 5 l&otilde;ike 3 kohaselt koostatud suunistega: </eesti>
<inglise> (a) the data shall include appropriate details on the condition intended to be treated and a justification of the life-threatening or seriously debilitating or serious and chronic nature of the condition supported by scientific or medical references; </inglise>
<eesti> a) andmed peavad sisaldama vajalikke &uuml;ksikasju ravida kavatsetava haigusseisundi kohta ja teaduslike v&otilde;i meditsiiniliste viidetega toetatud p&otilde;hjendust haigusseisundi eluohtliku v&otilde;i t&otilde;siselt invaliidistava v&otilde;i t&otilde;sise ja kroonilise olemuse kohta; </eesti>
<inglise> (b) the documentation submitted by the sponsor shall include data on all costs that the sponsor has incurred in the course of developing the medicinal product; </inglise>
<eesti> b) sponsori esitatud dokumentatsioonis peavad olema andmed k&otilde;igi kulude kohta, mis sponsorile on selle ravimi arendamise k&auml;igus tekkinud; </eesti>
<inglise> (c) the documentation provided shall include details of any grants, tax incentives or other cost recovery provisions received either within the Community or in third countries; </inglise>
<eesti> c) esitatud dokumentatsioonis peavad olema &uuml;ksikasjad k&otilde;igi &uuml;henduses v&otilde;i kolmandates riikides saadud toetuste, maksusoodustuste v&otilde;i kulude muude katmisviiside kohta; </eesti>
<inglise> (d) in cases where the medicinal product is already authorised for any indication or where the medicinal product is under investigation for one or more other indications, a clear explanation of and justification for the method that is used to apportion the development costs among the various indications shall be provided; </inglise>
<eesti> d) juhtudel, kui ravimil on juba luba &uuml;ksk&otilde;ik millise n&auml;idustuse jaoks v&otilde;i kui ravimit uuritakse &uuml;he v&otilde;i mitme muu n&auml;idustuse suhtes, tuleb esitada arusaadav selgitus, kuidas arenduskulusid mitmesuguste n&auml;idustuste vahel jagatakse, ja p&otilde;hjendada meetodit; </eesti>
<inglise> (e) a statement of and justification for all development costs that the sponsor expects to incur after the submission of the application for designation shall be provided; </inglise>
<eesti> e) tuleb esitada k&otilde;igi arenduskulude aruanne, mis sponsoril t&otilde;en&auml;oliselt tekivad p&auml;rast nimetamistaotluse esitamist, ja p&otilde;hjendada neid; </eesti>
<inglise> (f) a statement of and justification for all production and marketing costs that the sponsor has incurred in the past and expects to incur during the first 10 years that the medicinal product is authorised shall be provided; </inglise>
<eesti> f) tuleb esitada k&otilde;igi tootmis- ja turustuskulude aruanne, mis sponsorile on varem tekkinud ja eeldatavasti tekivad esimese 10 aasta jooksul p&auml;rast ravimi lubamist, ja p&otilde;hjendada neid; </eesti>
<inglise> (g) an estimate and justification for the expected revenues from sales of the medicinal product in the Community during the first 10 years after authorisation; </inglise>
<eesti> g) tuleb esitada hinnang ravimi m&uuml;&uuml;gist &uuml;henduses eeldatavasti saadava tulu kohta esimese 10 aasta jooksul p&auml;rast loa saamist ja p&otilde;hjendada seda; </eesti>
<inglise> (h) all cost and revenue data shall be determined in accordance with generally accepted accounting practices and shall be certified by a registered accountant in the Community; </inglise>
<eesti> h) k&otilde;ik andmed kulude ja tulude kohta m&auml;&auml;ratakse kindlaks vastavalt &uuml;ldtunnustatud raamatupidamistavadele ja neid peab kinnitama &uuml;henduses registreeritud raamatupidaja; </eesti>
<inglise> (i) the documentation provided shall include information on the prevalence and incidence in the Community of the condition for which the medicinal product would be administered at the time at which the application for designation is submitted. </inglise>
<eesti> i) esitatud dokumentatsioon peab sisaldama teavet, millise haigusseisundi puhul ravimit kavatsetakse kasutada, samuti selle leviku ja esinemissageduse kohta nimetamistaotluse esitamise ajal. </eesti>
<inglise> 3. </inglise>
<eesti> 3. </eesti>
<inglise> Existence of other methods of diagnosis, prevention or treatment </inglise>
<eesti> Muude diagnoosi-, v&auml;ltimis- v&otilde;i ravimeetodite olemasolu </eesti>
<inglise> An application for designation of a medicinal product as an orphan medicinal product may be submitted in accordance with either paragraph 1 or paragraph 2 of this Article. </inglise>
<eesti> Taotluse ravimi nimetamiseks harva kasutatavaks ravimiks v&otilde;ib esitada vastavalt k&auml;esoleva artikli l&otilde;ikele 1 v&otilde;i l&otilde;ikele 2. </eesti>
<inglise> Irrespective of whether an application for designation is submitted in accordance with paragraph 1 or 2, the sponsor must additionally establish that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question, or if such method exists that the medicinal product will be of significant benefit to those affected by that condition. </inglise>
<eesti> Olenemata sellest, kas nimetamistaotlus esitatakse vastavalt l&otilde;ikele 1 v&otilde;i 2, peab sponsor t&auml;iendavalt t&otilde;endama, et k&otilde;nealuse haigusseisundi diagnoosiks, v&auml;ltimiseks v&otilde;i raviks ei ole muud rahuldavat meetodit v&otilde;i, kui selline meetod on olemas, et ravim toob selle haigusseisundi all kannatajatele m&auml;rkimisv&auml;&auml;rset kasu. </eesti>
<inglise> For the purpose of establishing, pursuant to Article 3(1) (b) of Regulation (EC) No 141/2000 that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question, or if such method exists that the medicinal product will be of significant benefit to those affected by that condition, the following rules shall apply: </inglise>
<eesti> Selleks et vastavalt m&auml;&auml;ruse (E&Uuml;) nr 141/2000 artikli 3 l&otilde;ike 1 punktile b t&otilde;estada, et k&otilde;nealuse haigusseisundi diagnoosiks, v&auml;ltimiseks v&otilde;i raviks ei ole rahuldavat meetodit v&otilde;i, kui selline meetod on olemas, et ravim toob selle haigusseisundi all kannatajatele m&auml;rkimisv&auml;&auml;rset kasu, kohaldatakse j&auml;rgmisi eeskirju: </eesti>
<inglise> (a) details of any existing diagnosis, prevention or treatment methods of the condition in question that have been authorised in the Community shall be provided, making reference to scientific and medical literature or other relevant information. </inglise>
<eesti> a) esitatakse k&otilde;ik k&otilde;nealuse haigusseisundi &uuml;henduses lubatud diagnoosi-, v&auml;ltimis- v&otilde;i ravimeetodite &uuml;ksikasjad, viidates teadus- ja meditsiinikirjandusele v&otilde;i muule asjakohasele teabele. </eesti>
<inglise> These may include authorised medicinal products, medical devices or other methods of diagnosis, prevention or treatment which are used in the Community; </inglise>
<eesti> Siia v&otilde;ivad kuuluda &uuml;henduses kasutatavad lubatud ravimid, meditsiiniseadmed v&otilde;i muud diagnoosi-, v&auml;ltimis- v&otilde;i ravimeetodid; </eesti>
<inglise> (b) either a justification as to why the methods referred to in paragraph (a) are not considered satisfactory; </inglise>
<eesti> b) esitatakse kas p&otilde;hjendus, miks l&otilde;ikes a nimetatud meetodeid ei peeta rahuldavaks, </eesti>
<inglise> or </inglise>
<eesti> v&otilde;i </eesti>
<inglise> (c) a justification for the assumption that the medicinal product for which designation is sought will be of significant benefit to those affected by the condition. </inglise>
<eesti> c) p&otilde;hjendatakse, et ravim, millele taotletakse harva kasutatava ravimi nimetust, toob haigusseisundi all kannatajatele m&auml;rkimisv&auml;&auml;rset kasu. </eesti>
<inglise> 4. </inglise>
<eesti> 4. </eesti>
<inglise> General provisions </inglise>
<eesti> &Uuml;lds&auml;tted </eesti>
<inglise> (a) A sponsor applying for designation of a medicinal product as an orphan medicinal product shall apply for designation at any stage of the development of the medicinal product before the application for marketing authorisation is made. </inglise>
<eesti> a) Sponsor, kes esitab taotluse ravimi nimetamiseks harva kasutatavaks ravimiks, taotleb nimetust &uuml;ksk&otilde;ik millisel ravimi arendusetapil enne m&uuml;&uuml;giloa taotluse esitamist. </eesti>
<inglise> An application for designation may however be submitted for a new therapeutic indication for an already authorised medicinal product. </inglise>
<eesti> Samuti v&otilde;ib esitada nimetamistaotluse juba loa saanud ravimi uue n&auml;idustuse kohta. </eesti>
<inglise> In this case, the marketing authorisation holder shall apply for a separate marketing authorisation which will cover only the orphan indication(s). </inglise>
<eesti> Sel juhul taotleb m&uuml;&uuml;giloa valdaja eraldi m&uuml;&uuml;giluba, mis h&otilde;lmab ainult harva esinevat n&auml;idustust (esinevaid n&auml;idustusi). </eesti>
<inglise> (b) More than one sponsor may obtain designation as an orphan medicinal product for the same medicinal product intended to prevent, treat or diagnose the same disease or condition, provided that a complete application for designation as laid down by the guidelines specified in Article 5(3) is submitted in each case. </inglise>
<eesti> b) Harva kasutatava ravimi nimetuse samale ravimile, mis on m&otilde;eldud sama haiguse v&otilde;i haigusseisundi v&auml;ltimiseks, ravimiseks v&otilde;i diagnoosiks, v&otilde;ivad saada mitu sponsorit sel juhul, kui iga&uuml;ks neist on esitanud artikli 5 l&otilde;ikes 3 nimetatud suunistes etten&auml;htud t&auml;ieliku nimetamistaotluse. </eesti>
<inglise> (c) Where a medicinal product is designated by the Committee for Orphan Medicinal Products reference to the criteria for designation will be made either to Article 2(1) or to Article 2(2) of this Regulation. </inglise>
<eesti> c) Kui harva kasutatavate ravimite komitee annab ravimile harva kasutatava ravimi nimetuse, viidatakse k&auml;esoleva m&auml;&auml;ruse artikli 2 l&otilde;ike 1 v&otilde;i artikli 2 l&otilde;ike 2 nimetamiskriteeriumidele. </eesti>
<inglise> Article 3 </inglise>
<eesti> Artikkel 3 </eesti>
<inglise> Definitions </inglise>
<eesti> M&otilde;isted </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> The definitions in Article 2 of Regulation (EC) No 141/2000 apply to those terms when used in this Regulation: </inglise>
<eesti> K&auml;esolevas m&auml;&auml;ruses kasutatakse j&auml;rgmisi m&auml;&auml;ruse (E&Uuml;) nr 141/2000 artikli 2 m&otilde;isteid: </eesti>
<inglise> - "substance" means a substance used in the manufacture of a medicinal product for human use as defined in Article 1 of Directive 65/65/EEC. </inglise>
<eesti> aine - direktiivi 65/65/EM&Uuml; artiklis 1 m&auml;&auml;ratletud inimtervishoius kasutatava ravimi tootmisel kasutatav aine. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> For the purposes of the implementation of Article 3 of Regulation (EC) No 141/2000 on orphan medicinal products, the following definition shall apply: </inglise>
<eesti> Harva kasutatavaid ravimeid k&auml;sitleva m&auml;&auml;ruse (E&Uuml;) nr 141/2000 artikli 3 rakendamisel kohaldatakse j&auml;rgmist m&auml;&auml;ratlust: </eesti>
<inglise> - "significant benefit" means a clinically relevant advantage or a major contribution to patient care. </inglise>
<eesti> m&auml;rkimisv&auml;&auml;rne kasu - kliiniline eelis v&otilde;i oluline panus patsientide hooldamisel. </eesti>
<inglise> 3. </inglise>
<eesti> 3. </eesti>
<inglise> For the purposes of the implementation of Article 8 of Regulation (EC) No 141/2000 on orphan medicinal products, the following definitions shall apply: </inglise>
<eesti> Harva kasutatavaid ravimeid k&auml;sitleva m&auml;&auml;ruse (E&Uuml;) nr 141/2000 artikli 8 rakendamisel kohaldatakse j&auml;rgmisi m&auml;&auml;ratlusi: </eesti>
<inglise> (a) "active substance" means a substance with physiological or pharmacological activity; </inglise>
<eesti> a) toimeaine - f&uuml;sioloogiliselt v&otilde;i farmakoloogiliselt toimiv aine; </eesti>
<inglise> (b) "similar medicinal product" means a medicinal product containing a similar active substance of substances as contained in a currently authorised orphan medicinal product, and which is intended for the same therapeutic indication; </inglise>
<eesti> b) sarnane ravim - ravim, mis sisaldab juba lubatud harva kasutatavas ravimis sisalduva toimeaine sarnast toimeainet v&otilde;i -aineid ja on m&otilde;eldud sama n&auml;idustuse jaoks; </eesti>
<inglise> (c) "similar active substance" means an identicial active substance, or an active substance with the same principal molecular structural features (but not necessarily all of the same molecular structural features) and which acts via the same mechanism. </inglise>
<eesti> c) sarnane toimeaine - identne v&otilde;i samade p&otilde;hiliste molekulaarstruktuuri omadustega (aga mitte tingimata k&otilde;igi samade molekulaarstruktuuri omadustega) toimeaine, mille toimemehhanism on sama; </eesti>
<inglise> This includes: </inglise>
<eesti> See h&otilde;lmab: </eesti>
<inglise> (1) isomers, mixture of isomers, complexes, esters, salts and non-covalent derivatives of the original active substance, or an active substance that differs from the original active substance only with respect to minor changes in the molecular structure, such as a structural analogue; </inglise>
<eesti> 1) algup&auml;rase toimeaine isomeere, isomeeride segusid, komplekse, estreid, soolasid ja mittekovalentseid derivaate v&otilde;i toimeainet, mis erineb algup&auml;rasest toimeainest ainult molekulaarstruktuuri t&auml;htsusetute muutuste poolest nagu struktuuranaloog, </eesti>
<inglise> or </inglise>
<eesti> v&otilde;i </eesti>
<inglise> (2) the same macromolecule or one that differs from the original macromolecule only with respect to changes in the molecular structure such as: </inglise>
<eesti> 2) sama makromolekuli v&otilde;i makromolekuli, mis erineb algup&auml;rasest ainult molekulaarstruktuuri muudatuste v&otilde;rra, nagu: </eesti>
<inglise> (2.1) proteinaceous substances where: </inglise>
<eesti> 2.1. valkained juhul, kui: </eesti>
<inglise> - the difference is due to infidelity of transcription or translation, </inglise>
<eesti> - erinevus tuleneb transkriptsiooni v&otilde;i translatsiooni ebat&auml;psusest, </eesti>
<inglise> - the difference in structure between them is due to post-translational events (such as different glycosylation patterns) or different tertiary structures, </inglise>
<eesti> - nendevaheline struktuuriline erinevus tuleneb translatsioonij&auml;rgsetest modifikatsioonidest (nagu erinevad gl&uuml;kos&uuml;leerimise mustrid) v&otilde;i erinevatest tertsiaarstruktuuridest, </eesti>
<inglise> - the difference in the amino acid sequence is not major. </inglise>
<eesti> - aminohapete j&auml;rjestuse erinevus ei ole suur. </eesti>
<inglise> Therefore, two pharmacologically related protein substances of the same group (for example, two biological compounds having the same International Non-proprietary name (INN) sub-stem) would normally be considered similar, </inglise>
<eesti> Seet&otilde;ttu loetakse tavaliselt sarnasteks kaht sama r&uuml;hma farmakoloogiliselt seotud valkainet (n&auml;iteks kaht bioloogilist &uuml;hendit, millel on sama rahvusvahelise mittekaubandusliku nimetuse (INN) alamnimetus), </eesti>
<inglise> - the monoclonal antibodies bind to the same target epitope. </inglise>
<eesti> - monoklonaalsed antikehad seostuvad sama sihtepitoobiga. </eesti>
<inglise> These would normally be considered similar; </inglise>
<eesti> Neid peetakse tavaliselt sarnasteks; </eesti>
<inglise> (2.2) polysaccharide substances having identical saccharide repeating units, even if the number of units varies and even if there are post-polymerisation modifications (including conjugation); </inglise>
<eesti> 2.2. pol&uuml;sahhariidsed ained, millel on korduvad sahhariidide &uuml;hikud, isegi juhul, kui &uuml;hikute arv muutub ja kui esinevad pol&uuml;merisatsioonij&auml;rgsed modifikatsioonid (kaasa arvatud konjugatsioon); </eesti>
<inglise> (2.3) polynucleotide substances (including gene transfer and antisense substances), consisting of two or more distinct nucleotides where: </inglise>
<eesti> 2.3. pol&uuml;nukleotiidsed ained (kaasa arvatud geeni&uuml;lekandega seotud ja antisense-ained), mis sisaldavad kaht v&otilde;i rohkemat eristuvat nukleotiidi, kui: </eesti>
<inglise> - the difference in the nucleotide sequence of the purine and pyrimidine bases or their derivatives is not major. </inglise>
<eesti> - nende derivaatide puriin- ja p&uuml;rimidiinaluste nukleotiidij&auml;rjestuse erinevus ei ole suur. </eesti>
<inglise> Therefore for antisense substances, the addition or deletion of nucleotide(s) not significantly affecting the kinetics of hybridisation to the target would normally be considered similar. </inglise>
<eesti> Seet&otilde;ttu loetakse tavaliselt antisense-ainete puhul sarnaseks sihtm&auml;rgile nukleotiidi(de) lisamist v&otilde;i lahutamist, mis ei m&otilde;juta m&auml;rkimisv&auml;&auml;rselt h&uuml;bridisatsioonikineetikat sihtm&auml;rgile seondumisel. </eesti>
<inglise> For gene transfer substances, unless the differences in the sequence were significant the substances would normally be considered similar, </inglise>
<eesti> Geeni&uuml;lekandega seotud ained loetakse tavaliselt sarnasteks, kui j&auml;rjestuse erinevused ei ole m&auml;rkimisv&auml;&auml;rsed, </eesti>
<inglise> - the difference in structure between them relates to modifications to the ribose or deoxyribose sugar backbone or to the replacement of the backbone by synthetic analogues, </inglise>
<eesti> - nende struktuuriline erinevus seisneb riboosi v&otilde;i deoks&uuml;riboosi suhkur-fosfaat selgroo modifikatsioonides v&otilde;i selgroo asendamises s&uuml;nteetiliste analoogidega, </eesti>
<inglise> - the difference is in the vector or transfer system; </inglise>
<eesti> - erinevus on vektor- v&otilde;i &uuml;lekandes&uuml;steemis; </eesti>
<inglise> (2.4) closely related complex partly definable substances (such as two related viral vaccines, or two related cell therapy products); </inglise>
<eesti> 2.4. tihedalt seotud osaliselt defineeritavad ained (nagu kaks seotud viiruslikku vaktsiini v&otilde;i kaks seotud rakuteraapiatoodet); </eesti>
<inglise> or </inglise>
<eesti> v&otilde;i </eesti>
<inglise> (3) the same radiopharmaceutical active substance, or one differing from the original in radionuclide, ligand, site of labelling or molecule-radionuclide coupling mechanism linking the molecule and radionuclide provided that it acts via the same mechanism; </inglise>
<eesti> 3) sama radiofarmatseutiline toimeainet v&otilde;i ainet, mis erineb algup&auml;randist radionukliidi, ligandi, m&auml;rgistamiskoha v&otilde;i molekuli ja radionukliiti &uuml;hendava molekuli-radionukliidi sidumismehhanismi poolest, kui ta toimemehhanism on sama; </eesti>
<inglise> (d) "clinically superior" means that a medicinal product is shown to provide a significant therapeutic or diagnostic advantage over and above that provided by an authorised orphan medicinal product in one or more of the following ways: </inglise>
<eesti> d) kliiniline paremus - ravim annab v&otilde;rreldes lubatud harva kasutatava ravimiga t&otilde;estatult m&auml;rkimisv&auml;&auml;rseid ravi- v&otilde;i diagnostikaeeliseid &uuml;hel v&otilde;i mitmel j&auml;rgmisel viisil: </eesti>
<inglise> (1) greater efficacy than an authorised orphan medicinal product (as assessed by effect on a clinically meaningful endpoint in adequate and well controlled clinical trials). </inglise>
<eesti> 1) suurem t&otilde;husus kui lubatud harva kasutataval ravimil (hinnatuna m&otilde;ju kliiniliselt olulise l&otilde;pptulemusele seisukohalt piisavate ja korralikult kontrollitud kliiniliste uuringute alusel). </eesti>
<inglise> Generally, this would represent the same kind of evidence needed to support a comparative efficacy claim for two different medicinal products. </inglise>
<eesti> &Uuml;ldiselt t&auml;hendaks see samasugust t&otilde;estust, nagu vajatakse kahe erineva ravimi t&otilde;hususe v&otilde;rdlemisel. </eesti>
<inglise> Direct comparative clinical trials are generally necessary, however comparisons based on other endpoints, including surrogate endpoints may be used. </inglise>
<eesti> Tavaliselt on vaja otseseid v&otilde;rdlevaid kliinilisi uuringuid, kasutada v&otilde;ib ka muudel l&otilde;pptulemustel, sealjuures asendustulemustel p&otilde;hinevaid v&otilde;rdlusi. </eesti>
<inglise> In any case, the methodological approach should be justified; </inglise>
<eesti> Igal juhul peab metodoloogiline l&auml;henemine olema p&otilde;hjendatud; </eesti>
<inglise> or </inglise>
<eesti> v&otilde;i </eesti>
<inglise> (2) greater safety in a substantial portion of the target population(s). </inglise>
<eesti> 2) suurem turvalisus sihtpopulatsiooni(de) m&auml;rkimisv&auml;&auml;rses osas. </eesti>
<inglise> In some cases direct comparative clinical trials will be necessary; </inglise>
<eesti> M&otilde;nedel juhtudel on vaja otseseid v&otilde;rdlevaid kliinilisi uuringuid; </eesti>
<inglise> or </inglise>
<eesti> v&otilde;i </eesti>
<inglise> (3) in exceptional cases, where neither greater safety nor greater efficacy has been shown, a demonstration that the medicinal product otherwise makes a major contribution to diagnosis or to patient care. </inglise>
<eesti> 3) erandjuhtudel, kui ei ilmne ei suurem turvalisus ega suurem t&otilde;husus, t&otilde;estus, et ravim annab muul viisil olulise panuse diagnoosimisel v&otilde;i patsientide hooldamisel. </eesti>
<inglise> Article 4 </inglise>
<eesti> Artikkel 4 </eesti>
<inglise> Entry into force </inglise>
<eesti> J&otilde;ustumine </eesti>
<inglise> This Regulation shall enter into force on the day following its adoption by the Commission and shall apply from the same day. </inglise>
<eesti> K&auml;esolev m&auml;&auml;rus j&otilde;ustub j&auml;rgmisel p&auml;eval p&auml;rast selle vastuv&otilde;tmist komisjonis ja seda kohaldatakse samast p&auml;evast alates. </eesti>
<inglise> This Regulation shall be binding in its entirety and directly applicable in all Member States. </inglise>
<eesti> K&auml;esolev m&auml;&auml;rus on tervikuna siduv ja vahetult kohaldatav k&otilde;ikides liikmesriikides. </eesti>
<inglise> Done at Brussels, 27 April 2000. </inglise>
<eesti> Br&uuml;ssel, 27. aprill 2000 </eesti>
<inglise> For the Commission Erkki Liikanen Member of the Commission </inglise>
<eesti> Komisjoni nimel komisjoni liige Erkki LIIKANEN </eesti>
<inglise> (1) OJ L 18, 22.1.2000, p. 1. </inglise>
<eesti> (1) E&Uuml;T L 18, 22.01.2000, lk 1. </eesti>
 